UroGen Pharma Ltd. - Ordinary Shares (URGN)

UroGen Pharma shares are surging this week after the company gained FDA approval for ZUSDURI. The positive clinical trial results and an analyst upgrade fueled a significant stock price increase.

Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

FDA approves UroGen's Zusduri for recurrent low-grade bladder cancer, offering a non-surgical alternative with sustained response outcomes.

The new price target of $30 implies a near 171% upside to the stock’s closing price of $11.08 on Thursday.

Curious to know what's happening on the US markets one hour before the close of the markets on Thursday? Join us as we explore the top gainers and losers in today's session.

Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session.

Analyst Selvaraju downgrades UroGen after FDA panel setback dims approval prospects for key bladder cancer drug UGN-102.

UroGen shares traded lower Wednesday after the ODAC of the Food and Drug Administration voted against the benefit/risk of UGN-102 (mitomycin) for intravesical solution.

The Food and Drug Administration is expected to conclude its review of UroGen’s UGN-102 application by June 13.

Here are the top movers in Friday's session, showcasing the stocks with significant price changes.

Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.

Let's delve into the US markets on Friday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.

UroGen Pharma reports strong long-term data for Jelmyto and UGN-102 in cancer studies and shares promising early results for UGN-301 in bladder cancer.

URGN stock results show that UroGen Pharma missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

UroGen Pharma stock had its Relative Strength (RS) Rating upgraded to 91 Thursday, up from 87 a day earlier.